证券代码:300463 证券简称:迈克生物 公告编号:2025-040 2、因公司回购专用证券账户中持有的 3,958,000 股不参与本次权益分派，本次权益分派实 施后，根据股票市值不变原则，实施权益分派前后公司总股本保持不变，现金分红总额分摊到 每一股的比例将减小。本次权益分派实施后，按公司总股本折算每 10 股现金分红为=现金分 红总额/总股本*10 股=（63,285,205.36 元/612,469,590 股）*10 股=1.033279 元（保留六位小数， 最后一位直接截取，不四舍五入）。 3、本次权益分派实施后，除权除息参考价格=股权登记日收盘价-0.1033279 元/股。 一、股东大会审议通过权益分派方案的情况 1、公司 2024 年年度股东大会审议通过 2024 年年度权益分派预案 迈克生物股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 重要内容提示： 1、截至本公告日，迈克生物股份有限公司（以下简称"公司"）回购专用证券账户中持有 的股份 3,958,000 股不参与本次权益分派，本次权益分 ...

证券代码:300463 证券简称:迈克生物 公告编号:2025-039 迈克生物股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 特别提示： 一、会议的召开和出席情况 迈克生物股份有限公司（以下简称："公司"）2024 年年度股东大会于 2025 年 5 月 19 日 （星期一）在公司会议室以现场投票和网络投票相结合的方式召开。会议通知于 2025 年 4 月 29 日以公告形式发出。通过深圳证券交易所系统进行网络投票的具体时间为：2025 年 5 月 19 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳证券交易所互联网投票系统投票的 具体时间为：2025 年 5 月 19 日 9:15-15:00 期间的任意时间。 本次股东大会由公司董事会召集，董事长唐勇先生主持本次会议。公司全部董事、监事出 席了本次会议；公司全部高级管理人员列席了本次会议。上海市锦天城律师事务所委派张灵芝、 朱憬律师见证了本次会议并出具法律意见书。本次会议的召集、召开与表决程序符合法律、行 政法规、部门 ...

上海市锦天城律师事务所 关于迈克生物股份有限公司 2024 年年度股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11/12 楼 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于迈克生物股份有限公司 2024 年年度股东大会的 法律意见书 致：迈克生物股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受迈克生物股份有限公司 （以下简称"公司"）委托，就公司召开 2024 年年度股东大会（以下简称"本 次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称《公司 法》）、《上市公司股东会规则》等法律、法规、规章和其他规范性文件以及《迈 克生物股份有限公司章程》（以下简称《公司章程》）的有关规定，出具本法律 意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核查和验证，核查了本所认为出 ...

Group 1 - The core viewpoint of the news is that Maike Biological's stock performance and financial metrics indicate a significant decline in revenue and profit, alongside a high price-to-earnings (PE) ratio compared to industry averages [1][2][3] Group 2 - As of May 16, Maike Biological's stock closed at 12.07 yuan, with a PE ratio of 243.63, marking a new low in 28 days and a total market capitalization of 7.393 billion yuan [1] - The average PE ratio in the medical device industry is 49.40, with a median of 36.13, placing Maike Biological at the 117th position in the industry ranking [1][3] - For the first quarter of 2025, the company reported a revenue of 510 million yuan, a year-on-year decrease of 17.22%, and a net profit of 23.98 million yuan, down 80.09% year-on-year, with a gross margin of 56.76% [2]

Investment Rating - The investment rating for Maccura Biotechnology is maintained as BUY with a target price of RMB13.54, indicating a potential upside of 14% from the closing price of RMB11.90 as of May 15, 2025 [6][7]. Core Insights - Maccura's 2024 revenue and attributable net profit were RMB2,549 million and RMB127 million, respectively, reflecting declines of 12.0% and 59.4% year-on-year, primarily due to short-term policy headwinds and adjustments in the agency business [1][6]. - The proprietary business revenue showed resilience, increasing by 1.8% year-on-year to RMB1,913 million, suggesting robust growth in the main business segment [1]. - For the first quarter of 2025, revenue and attributable net profit fell by 17.2% and 80.1% year-on-year, attributed to ongoing transformation efforts and increased marketing spending [1]. Revenue Growth and Market Share - Maccura's CL reagents revenue in 2024 grew by 8% year-on-year to RMB1,029 million, supported by enhanced market recognition and the installation of 224 bioassay automation lines and 1,352 immunoassay analyzers [2]. - The company is expected to ship nearly 2,000 new CL analyzers in 2025, which will likely drive in-hospital reagent consumption and contribute to steady revenue growth and market share gains [2]. Segment Performance - The biochemistry segment experienced a revenue decline of 13.5% year-on-year in 2024, totaling RMB499 million, mainly due to price adjustments following inter-provincial VBP [3]. - Clinical testing revenue increased by 21.8% year-on-year to RMB214 million, with expectations for rapid growth in 2025 due to successful market penetration of clinical testing equipment [3]. - The agency business saw a significant revenue drop of 37.6% year-on-year to RMB612 million, indicating ongoing challenges in this segment [3]. Earnings Forecasts and Valuation - Earnings per share (EPS) estimates for 2025, 2026, and 2027 have been lowered by 44%, 46%, and 0% to RMB0.49, RMB0.58, and RMB0.70, respectively, due to short-term disruptions and increased marketing and R&D spending [4]. - The valuation of the IVD business is set at 28x 2025E PE, while the agency business is valued at 24x 2025E PE, compared to peers' averages of 29x and 24x [4].

证券代码：300463 证券简称：迈克生物 公告编号：2025-038 迈克生物股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 经迈克生物股份有限公司（以下简称"公司"）第六届董事会第三次会议审议通过了 《关于召开2024年年度股东大会的议案》，公司定于2025年5月19日（星期一）14:00召开 2024年年度股东大会，本次股东大会将采取现场投票和网络投票相结合的方式。会议召开 通知已于2025年4月29日披露在巨潮资讯网（http://www.cninfo.com.cn），公告编号：2025- 034。现将有关事项提示如下： 一、本次会议的基本情况 1、股东大会届次：2024年年度股东大会 2、会议召集人：公司董事会 3、会议召开的合规性：本次股东大会的召开符合有关法律、行政法规、部门规章、规 范性文件和《公司章程》的有关规定，公司第六届董事会第三次会议已经审议通过召开本 次股东大会的议案。 4、会议召开的日期、时间： （1）现场会议召开时间为：2025年5月19日（星期一）14:00 （2）网络投票 ...

Group 1 - The core viewpoint of the article highlights that Maike Biological has a high rolling price-to-earnings (PE) ratio of 238.79, significantly above the industry average of 49.84 and median of 36.59, indicating a potentially overvalued stock in the medical device sector [1][2] - As of the first quarter of 2025, four institutions hold shares in Maike Biological, with a total of 25.43 million shares valued at 331 million yuan [1] - The company specializes in the research, production, sales, and service of in vitro diagnostic products, being one of the first domestic IVD companies to establish a traceability system for measurement values [1] Group 2 - The latest financial results for the first quarter of 2025 show that Maike Biological achieved a revenue of 510 million yuan, representing a year-on-year decrease of 17.22%, and a net profit of 23.98 million yuan, down 80.09% from the previous year, with a gross profit margin of 56.76% [1] - In terms of market capitalization, Maike Biological is valued at 7.246 billion yuan, ranking 117th in the industry based on PE ratio [2] - The average PE ratio for the medical device industry is 49.84, with a median of 36.59, indicating that Maike Biological's valuation is significantly higher than its peers [2]

Group 1: Company Overview and Market Position - Mike Biotech Co., Ltd. is committed to enhancing investor value and strictly adheres to market value management regulations [2][3]. - The company has established a comprehensive market presence with 11 subsidiary channels and 23 offices, covering over 9,100 medical institutions [18]. Group 2: Financial Performance - In 2024, the company reported a revenue of CNY 2.549 billion and a net profit of CNY 127 million; for Q1 2025, revenue was CNY 510 million with a net profit of CNY 24 million [11][14]. - Cumulative cash dividends since listing amount to CNY 1.214 billion, with a proposed dividend of CNY 63 million for 2024, increasing the payout ratio to 50% of net profit [4]. Group 3: Value Management and Investor Relations - The company has implemented a value management system since March 2024, focusing on compliance and maximizing shareholder interests [3][4]. - From 2024 to Q1 2025, the company conducted over 200 investor interactions and issued four investor relations activity records [5][6]. Group 4: Challenges and Strategic Responses - The company faced a decline in performance due to goodwill impairment losses of CNY 94 million and market adjustments related to procurement policies [14][23]. - The IVD industry is experiencing significant pressure from policy changes, with over 70% of companies reporting revenue declines in 2024 [24]. Group 5: Future Outlook and Growth Strategies - The company aims to increase its overseas market share to 30% by 2030, with a projected overseas sales revenue of CNY 160 million in 2024, a 60% increase year-on-year [19][21]. - R&D investment for 2024 was CNY 419 million, representing 21.91% of revenue from self-developed products, focusing on automation and systematization [24].

| 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 1.信息披露 | 无 | 不适用 | | 2.公司内部制度的建立和执行 | 无 | 不适用 | | 3．"三会"运作 | 无 | 不适用 | | 4.控股股东及实际控制人变动 | 无 | 不适用 | | 5.募集资金存放及使用 | 无 | 不适用 | | 6.关联交易 | 无 | 不适用 | | 7.对外担保 | 无 | 不适用 | | 8.收购、出售资产 | 无 | 不适用 | | 9.其他业务类别重要事项（包括 对外投资、风险投资、委托理财、 | 无 | 不适用 | | 财务资助、套期保值等） | | | | 10．发行人或者其聘请的中介机 | 无 | 不适用 | | 构配合保荐工作的情况 | | | | 11.其他（包括经营环境、业务发 展、财务状况、管理状况、核心 | 无 | 不适用 | | 技术等方面的重大变化情况） | | | 招商证券股份有限公司 关于迈克生物股份有限公司 2024 年度持续督导跟踪报告 | 保荐机构名称：招商证券股份有限公司 | 被保荐公司简称：迈克生物 | | --- | --- | | ...

迈克生物股份有限公司 持续督导保荐总结报告书 招商证券股份有限公司 关于迈克生物股份有限公司 向特定对象发行股票持续督导保荐总结报告书 招商证券股份有限公司（以下简称"招商证券"）作为迈克生物股份有限公司 （以下简称"迈克生物"、"公司"）向特定对象发行股票的保荐机构，持续督导期 限截至 2024 年 12 月 31 日。目前，持续督导期已经届满，招商证券根据《证券 发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券 交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》及《深圳证券 交易所上市公司自律监管指引第 13 号—保荐业务》等有关规定，出具本保荐总 结报告书。 2、本机构及本人自愿接受中国证监会对保荐总结报告书相关事项进行的任 何质询和调查。 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施 。 二、保荐机构基本情况 | 项目 | 内容 | | --- | --- | | 保荐机构名称 | 招商证券股份有限公司 | | 注册地址 | 深圳市福田区福田街道福华一路 号 111 | | 主要办公地址 | 深圳市福田区福田街道福 ...